1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Earnings

‘New’ B+L? Wait Until Bausch Health Sells Stake

 
• By Malcolm Spicer

Analysts hold back on predicting new heights for B+L until full split from parent firm. It reported Q4 revenue up 9% to $1.28bn and full-year revenue up 16% to $4.79bn.

(Source: Shutterstock/Citeline)

Bausch + Lomb Corp. CEO Brent Saunders says customers talk of a “new” company emerging since he became CEO two years ago. He hedges on making the claim, however, and market analysts hold back on predicting new heights for B+L until it fully splits from parent firm Bausch Health Companies Inc.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

US Q1 Consumer Health Earnings Preview: Concern Unavoidable For Impact From ‘T’ Word

 
• By Malcolm Spicer

Concern is unavoidable for most marketers of OTC drugs and dietary supplements in the US. As Canaccord Genuity analysts said in a 15 April research note, “uncertainty remains about how the tariff situation will play out.”

Euro Q1 Consumer Health Earnings Preview: Haleon, Reckitt, Bayer

 
• By Tom Gallen

Major Europe-based consumer health players Haleon, Reckitt and Bayer feature in this sales and earnings preview, which highlights what to look out for as these three firms report their Q1 2025 results over the coming weeks.

Futura Records First Profits And Targets Eroxon Extension

 
• By Tom Gallen

The US launch of Eroxon ED treatment by Haleon helped Futura Medical record its first ever profit in 2024. The UK firm will now look to capitalize this by seeking US and EU approval for a more potent Eroxon line extension.

‘The Only Certainty Is Uncertainty’ In The UK’s Consumer Health Market

 
• By David Ridley

While uncertainty might reign in the UK consumer health market - which grew by by 8% to £4.1bn ($5.3bn) in 2024 - “opportunity is everywhere” according to NielsenIQ health and beauty insights manager Alex Heffernan.

More from Wellness

Accelerating Natural Options Among US FDA’s Steps For Removing Petroleum-Based Food Dyes

 
• By Malcolm Spicer

HHS Secretary Kennedy commends food companies for cooperating, but also says, “We have them on the run now and we are going to win this battle. And four years from now, we're going to have most of these products off the market.”

US Q1 Consumer Health Earnings Preview: Concern Unavoidable For Impact From ‘T’ Word

 
• By Malcolm Spicer

Concern is unavoidable for most marketers of OTC drugs and dietary supplements in the US. As Canaccord Genuity analysts said in a 15 April research note, “uncertainty remains about how the tariff situation will play out.”

US Plans End To Petroleum-Based Dyes In Food

 
• By Malcolm Spicer

HHS Secretary Robet F. Kennedy Jr. and FDA Commissioner Marty Makary to announce planned changes as “a major step forward” as part of Kennedy’s “Make America Healthy Again” campaign President Trump has adopted for his administration.